BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease
Retrieved on:
Thursday, August 5, 2021
Company, Chemokine, Form 8-K, Alzheimer's disease, Ascites, Insulin, Neuroinflammation, Memory, Inflammation, Mayo Clinic, Brain, Liver disease, Insulin resistance, Erk, Fast track (FDA), Metabolism, Pathology, Neurodegeneration, Neuroscience, Tumor necrosis factor, Dementia, AAIC, Cancer, Trial of the century, Patient, Cognition, Extracellular signal-regulated kinases, SEC, Diabetes, Hand, Doctor of Philosophy, Survival, Phosphorylation, Conference, Nasdaq, GLOBE, Pharmaceutical industry, Medical device
The NM101 study ( NCT04669028 ) is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.
Key Points:
- The NM101 study ( NCT04669028 ) is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.
- The mechanistic basis for the study design was recently published in a peer-reviewed article in Neurodegenerative Disease Management ( https://doi.org/10.2217/nmt-2021-0022 ).
- The Company is conducting a Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028).
- A Phase 2 study of NE3107 in Parkinsons Disease is planned for later this year, and related compounds have additional potential to treat certain cancers.